Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

04-963 Anti-CTLA4 (CD152) Antibody, clone 9H10

Anti-CTLA4 (CD152) Antibody, clone 9H10 is an antibody against CTLA4 (CD152) for use in WB, FC & IP.

Anti-CTLA4 (CD152) Antibody, clone 9H10 MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Research Category: Inflammation & Immunology Research Sub-Category: Transcription Factors, Inflammation & Autoimmune Mechanisms Gene Symbol: CD, CD152, CD28, CELIAC3, CTLA-4, GSE, ICOS, IDDM12, OTTHUMP00000163781 UniProt Number: P16410
04-963
100 µg  
Purchase on Sigma-Aldrich

Oferty specjalne

Przegląd

Replacement Information

Oferty specjalne

100% Performance Guaranteed

Tabela kluczowych gatunków

Species ReactivityKey ApplicationsHostFormatAntibody Type
MWB, FC, IPHtPurifiedMonoclonal Antibody
Description
Catalogue Number04-963
DescriptionAnti-CTLA4 (CD152) Antibody, clone 9H10
Alternate Names
  • CD152 antigen
  • Cytotoxic T-lymphocyte-associated antigen 4
  • celiac disease 3
  • cytotoxic T-lymphocyte-associated protein 4
  • cytotoxic T-lymphocyte-associated serine esterase-4
  • ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Background InformationCTLA4, Cytotoxic T lymphocyte antigen 4, also known as CD152, belongs to the family of immunoglobins. It is widely expressed on activated T lymphocytes and is involved in the maintenance of immune tolerance. CTLA4 is a homolog for CD28. They are able to bind to B7-1 and B7-2; however, CTLA4 is able to bind to both with a higher affinity. Defects in CTLA4 have been linked to Rheumatoid arthritis, Addisons disease, Graves disease and many other autoimmune diseases.
References
Product Information
FormatPurified
Control
  • Mouse spleen cell lysate
PresentationPurified hamster monoclonal IgG in buffer containing 0.1 M Tris-Glycine (pH 7.4) with 150 mM NaCl and 0.05% sodium azide.
Quality LevelMQ100
Applications
ApplicationAnti-CTLA4 (CD152) Antibody, clone 9H10 is an antibody against CTLA4 (CD152) for use in WB, FC & IP.
Key Applications
  • Western Blotting
  • Flow Cytometry
  • Immunoprecipitation
Application NotesFlow Cytometry Analysis: Representative images from a previous lot of primary antibody that was biotinylated. Results with 04-963 are expected to be similar if used directly with an anti-Syrian hamster conjugated antibody, however because of the low expression of CTLA4 Fab fragmented goat anti-Syrian hamster biotin followed SA-fluorophore is recommended for best results.
FACS analysis of ConA (24 hours) stimulated BALB/C splenocytes for surface expression of CTLA-4 (CD152). Cells were stained with 10 ug of biotin-labeled hamster anti-CTLA-4 ,clone 9H10 (open histogram) or with PE-Sav secondary antibody alone (histogram, Figure B). Note the distinct signal difference between the control (dark control histogram) and test (clear histogram).
Immunoprecipitation: Clone 9H10 is widely used for immunoprecipitaiton of CTLA-4; recommended lysis buffers include 1% NP40; 0.5% triton X-100 with proteinase inhibitors; 1-5 µg of 9H10 is added to 300-500 µL of whole cell lysate or cell membrane protein preparations (250-500 mg/mL totall protein) and incubated 3-6 hours at 4°C, followed by capture with protein G beads following standard immunoprecipitation methods (Zhang, Y., et al., 1997).
Biological Information
ImmunogenMouse CTLA-4/human IgG1 fusion protein corresponding to residues surrounding CTLA4.
Clone9H10
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostHamster
SpecificityThis antibody recognizes CTLA4. Antibody 9H10 is specific for CTLA-4 by four criteria: (a) Reactivity against CTLA-4 Ig but not CD4 lg; (b) the ability to block CTLA-4 Ig binding to B7 transfectants; (c) the ability to stain activated T cells but not freshly isolated T cells; and (d) the ability to stain a CTLA-4 transfectant but not control transfectants (Krummel, M.F., et al., 1995).
IsotypeIgG
Species Reactivity
  • Mouse
Antibody TypeMonoclonal Antibody
Entrez Gene Number
Gene Symbol
  • CD
  • CD152
  • CD28
  • CELIAC3
  • CTLA-4
  • GSE
  • ICOS
  • IDDM12
  • OTTHUMP00000163781
Purification MethodProtein G Purified
UniProt Number
UniProt SummaryFUNCTION: Possibly involved in T-cell activation. Binds to B7-1 (CD80) and B7-2 (CD86).
SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
TISSUE SPECIFICITY: Widely expressed with highest levels in lymphoid tissues.
INVOLVEMENT IN DISEASE: Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Genetic variation in CTLA4 may be a cause of susceptibility to Graves disease (GRD) [MIM:275000]. GRD is an autoimmune disorder causing overactivity of the thyroid gland and hyperthyroidism.
Genetic variation in CTLA4 is the cause of susceptibility to insulin-dependent diabetes mellitus type 12 (IDDM12) [MIM:601388].
Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. Celiac disease [MIM:212750] is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive.
Genetic variations in CTLA4 are associated with susceptibility to hepatitis B virus infection (HBV infection) [MIM:610424]. Approximately one third of all cases of cirrhosis and half of all cases of hepatocellular carcinoma can be attributed to chronic HBV infection. HBV infection may result in subclinical or asymptomatic infection, acute self-limited hepatitis, or fulminant hepatitis requiring liver transplantation.
SEQUENCE SIMILARITIES: Contains 1 Ig-like V-type (immunoglobulin-like) domain.
Molecular Weight~30 kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceEvaluated by Western Blot in mouse spleen lysate.
Western Blot Analysis: 1 µg/mL of a biotinylated version of this antibody detected CTLA4 in 10 µg of mouse spleen lysate.
THIS ANTIBODY IS NO BIOTINYLATED.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable at 2-8°C for 1 year from date of receipt.
Packaging Information
Material Size100 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Numer katalogowy GTIN
04-963 04053252671722

Documentation

Anti-CTLA4 (CD152) Antibody, clone 9H10 MSDS

Title

Safety Data Sheet (SDS) 

Anti-CTLA4 (CD152) Antibody, clone 9H10 Certificates of Analysis

TitleLot Number
Anti-CTLA4 (CD152), clone 9H10 - 2395685 2395685
Anti-CTLA4 (CD152), clone 9H10 - 2299145 2299145
Anti-CTLA4 (CD152), clone 9H10 - 2316807 2316807
Anti-CTLA4 (CD152), clone 9H10 - 3251016 3251016
Anti-CTLA4 (CD152), clone 9H10 - 3762559 3762559
Anti-CTLA4 (CD152), clone 9H10 - NRG1704146 NRG1704146
Anti-CTLA4 (CD152), clone 9H10 -2522087 2522087
Anti-CTLA4 (CD152), clone 9H10 -2608446 2608446
Anti-CTLA4 (CD152), clone 9H10 -2654209 2654209
Anti-CTLA4 (CD152), clone 9H10 -2791198 2791198
Show more

Brochure

Title
Advancing cancer research: From hallmarks & biomarkers to tumor microenvironment progression